Sponsors    Modifications    and g   if an applicant engages in compounding, submit the most recent inspection report  i   conducted within two years before the application for licensure  and ii   A   conducted as part of the National Association of Boards of Pharmacy VerifiedPharmacy Program  or B   performed by the state licensing agency of the state in which the applicant is aresident and in accordance with the National Association of Boards of Pharmacy multistateinspection blueprint program.     As a prerequisite for renewal of a class D pharmacy license of a pharmacy thatengages in compounding, a licensee shall submit the most recent inspection report  a   conducted within two years before the application for renewal  and b   i   conducted as part of the National Association of Boards of Pharmacy VerifiedPharmacy Program  or ii   performed by the state licensing agency of the state in which the applicant is aresident and in accordance with the National Association of Boards of Pharmacy multistateinspection blueprint program. a  i  ii  iii  iv  v  vi  vii  viii  b   The requirements described in Subsections     a  i  through  vi  do not apply to alabel on the container of a drug that a health care provider administers to a patient at  i   a pharmaceutical administration facility  or ii   a hospital licensed under Title   , Chapter   , Health Care Facility Licensing andInspection Act.          b    .     A pharmacist may, in accordance with this section, administer a drug described inSubsection    .     Notwithstanding the provisions of Subsection      b         c  ii  B , thedivision shall make rules, in accordance with Title   G, Chapter  , Utah AdministrativeRulemaking Act, establishing training for a pharmacist to administer the following long actinginjectables intramuscularly  a   aripiprazole  b   paliperidone  c   risperidone  d   olanzapine  e   naltrexone  f   naloxone  and g   drugs approved and regulated by the United States Food and Drug Administrationfor the treatment of the Human Immunodeficiency Virus.     A pharmacist may not administer a drug listed under Subsection     unless thepharmacist  a   completes the training described in Subsection      b   administers the drug at a clinic or community pharmacy, as those terms are definedby the division, by administrative rule made in accordance with Title   G, Chapter  , UtahAdministrative Rulemaking Act  and c   is directed by the physician, as that term is defined in Section           or Section         , who issues the prescription to administer the drug.     Except as provided in Subsection    , this bill takes effect on May  ,     .     The amendments to Sections      b     and      b     take effect on October  ,    .Full text           PHARMACY PRACTICE ACT AMENDMENTS           GENERAL SESSION      STATE OF UTAH      Chief Sponsor   Evan J. Vickers      House Sponsor   Paul  Ray             LONG TITLE      General Description            This bill amends the Pharmacy Practice Act.       Highlighted Provisions             This bill                   requires certain Utah licensed nonresident pharmacies to submit to an inspection as       a prerequisite for licensure                   excludes drugs administered under certain conditions from certain drug container       labeling requirements                   permits certain pharmacists to administer long acting injectable drugs       intramuscularly under certain conditions  and                  makes technical changes.       Money Appropriated in this Bill             None       Other Special Clauses             This bill provides a special effective date.       Utah Code Sections Affected        AMENDS                  b    , as last amended by Laws of Utah     , Chapter                     b    , as last amended by Laws of Utah     , Chapter                     b    , as last amended by Laws of Utah     , Chapter          ENACTS                  b    , Utah Code Annotated                    Be it enacted by the Legislature of the state of Utah             Section  .  Section      b     is amended to read                  b    . Qualifications for licensure as a pharmacy.                 Each applicant for licensure under this section, except for those applying for a class       D license, shall              a   submit a written application in the form prescribed by the division              b   pay a fee as determined by the department under Section   J                    c   satisfy the division that the applicant, and each owner, officer, or manager of the       applicant have not engaged in any act, practice, or omission, which when considered with the       duties and responsibilities of a licensee under this section indicates there is cause to believe       that issuing a license to the applicant is inconsistent with the interest of the public s health,       safety, or welfare              d   demonstrate the licensee s operations will be in accordance with all federal, state,       and local laws relating to the type of activity engaged in by the licensee, including regulations       of the Federal Drug Enforcement Administration and Food and Drug Administration              e   maintain operating standards established by division rule made in collaboration       with the board  and             f   acknowledge the division s authority to inspect the licensee s business premises       pursuant to Section      b    .                 Each applicant applying for a class D license shall              a   submit a written application in the form prescribed by the division              b   pay a fee as determined by the department under Section   J                    c   present to the division verification of licensure in the state where physically located       and verification that such license is in good standing              d   provide a statement of the scope of pharmacy services that will be provided and a       detailed description of the protocol as described by rule by which pharmacy care will be       provided, including any collaborative practice arrangements with other health care       practitioners              e   sign an affidavit attesting that any healthcare practitioners employed by the       applicant and physically located in Utah have the appropriate license issued by the division and       in good standing   and              f   sign an affidavit attesting that the applicant will abide by the pharmacy laws and       regulations of the jurisdiction in which the pharmacy is located .   and             g   if an applicant engages in compounding, submit the most recent inspection report              i   conducted within two years before the application for licensure  and             ii   A   conducted as part of the National Association of Boards of Pharmacy Verified       Pharmacy Program  or             B   performed by the state licensing agency of the state in which the applicant is a       resident and in accordance with the National Association of Boards of Pharmacy multistate       inspection blueprint program.                 Each license issued under this section shall be issued for a single, specific address,       and is not transferable or assignable.            Section  .  Section      b     is amended to read                  b    . Term of license    Expiration    Renewal.                 Except as provided in Subsection    , each license issued under this chapter shall be       issued in accordance with a two year renewal cycle established by rule.  A renewal period may       be extended or shortened by as much as one year to maintain established renewal cycles or to       change an established renewal cycle.  Each license automatically expires on the expiration date       shown on the license unless renewed by the licensee in accordance with Section         .                 The duration of a pharmacy intern license may be no longer than              a   one year for a license issued under Subsection      b        b   or             b   five years for a license issued under Subsection      b        a .                 A pharmacy intern license issued under this chapter may not be renewed, but may       be extended by the division in collaboration with the board.                 As a prerequisite for renewal of a class D pharmacy license of a pharmacy that       engages in compounding, a licensee shall submit the most recent inspection report              a   conducted within two years before the application for renewal  and             b   i   conducted as part of the National Association of Boards of Pharmacy Verified       Pharmacy Program  or             ii   performed by the state licensing agency of the state in which the applicant is a       resident and in accordance with the National Association of Boards of Pharmacy multistate       inspection blueprint program.            Section  .  Section      b     is amended to read                  b    . Prescription orders    Information required    Alteration    Labels          Signatures    Dispensing in pharmacies.                 Except as provided in Section         . , the minimum information that shall be       included in a prescription order, and that may be defined by rule, is              a   the prescriber s name, address, and telephone number, and, if the order is for a       controlled substance, the patient s age and the prescriber s DEA number               b   the patient s name and address or, in the case of an animal, the name of the owner        and species of the animal               c   the date of issuance               d   the name of the medication or device prescribed and dispensing instructions, if        necessary               e   the directions, if appropriate, for the use of the prescription by the patient or animal        and any refill, special labeling, or other instructions               f   the prescriber s signature if the prescription order is written               g   if the order is an electronically transmitted prescription order, the prescribing        practitioner s electronic signature  and              h   if the order is a hard copy prescription order generated from electronic media, the        prescribing practitioner s electronic or manual signature.                  The requirement of Subsection     a  does not apply to prescription orders        dispensed for inpatients by hospital pharmacies if the prescriber is a current member of the        hospital staff and the prescription order is on file in the patient s medical record.                  Unless it is for a Schedule II controlled substance, a prescription order may be        dispensed by a pharmacist or pharmacy intern upon an oral prescription of a practitioner only if        the oral prescription is promptly reduced to writing.                  a   Except as provided under Subsection     b , a pharmacist or pharmacy intern        may not dispense or compound any prescription of a practitioner if the prescription shows        evidence of alteration, erasure, or addition by any person other than the person writing the        prescription.              b   A pharmacist or pharmacy intern dispensing or compounding a prescription may        alter or make additions to the prescription after receiving permission of the prescriber and may        make entries or additions on the prescription required by law or necessitated in the        compounding and dispensing procedures.                  a   Each drug dispensed shall have a label securely affixed to the container        indicating the following minimum information                a    i   the name, address, and telephone number of the pharmacy                b    ii   the serial number of the prescription as assigned by the dispensing pharmacy                c    iii   the filling date of the prescription or its last dispensing date                d    iv   the name of the patient, or in the case of an animal, the name of the owner        and species of the animal                e    v   the name of the prescriber                f    vi   the directions for use and cautionary statements, if any, which are contained in        the prescription order or are needed                g    vii   except as provided in Subsection    , the trade, generic, or chemical name,        amount dispensed and the strength of dosage form, but if multiple ingredient products with        established proprietary or nonproprietary names are prescribed, those products  names may be        used  and               h    viii   the beyond use date.              b   The requirements described in Subsections     a  i  through  vi  do not apply to a        label on the container of a drug that a health care provider administers to a patient at               i   a pharmaceutical administration facility  or              ii   a hospital licensed under Title   , Chapter   , Health Care Facility Licensing and        Inspection Act.                  A hospital pharmacy that dispenses a prescription drug that is packaged in a        multidose container to a hospital patient may provide the drug in the multidose container to the        patient when the patient is discharged from the hospital if               a   the pharmacy receives a discharge order for the patient  and              b   the pharmacy labels the drug with the               i   patient s name               ii   drug s name and strength               iii   directions for use of the drug, if applicable  and              iv   pharmacy s name and phone number.                  If the prescriber specifically indicates the name of the prescription product should        not appear on the label, then any of the trade, generic, chemical, established proprietary, and        established nonproprietary names and the strength of dosage form may not be included.                  Prescribers are encouraged to include on prescription labels the information        described in Section      b    .  in accordance with the provisions of that section.                  A pharmacy may only deliver a prescription drug to a patient or a patient s agent               a   in person at the pharmacy  or              b   via the United States Postal Service, a licensed common carrier, or supportive        personnel, if the pharmacy takes reasonable precautions to ensure the prescription drug is               i   delivered to the patient or patient s agent  or              ii   returned to the pharmacy.             Section  .  Section      b     is enacted to read                   b    . Administration of a long acting injectable drug therapy.                  A pharmacist may, in accordance with this section, administer a drug described in        Subsection    .                  Notwithstanding the provisions of Subsection      b         c  ii  B , the        division shall make rules, in accordance with Title   G, Chapter  , Utah Administrative        Rulemaking Act, establishing training for a pharmacist to administer the following long acting        injectables intramuscularly               a   aripiprazole               b   paliperidone               c   risperidone               d   olanzapine               e   naltrexone               f   naloxone  and              g   drugs approved and regulated by the United States Food and Drug Administration        for the treatment of the Human Immunodeficiency Virus.                  A pharmacist may not administer a drug listed under Subsection     unless the        pharmacist               a   completes the training described in Subsection                   b   administers the drug at a clinic or community pharmacy, as those terms are defined        by the division, by administrative rule made in accordance with Title   G, Chapter  , Utah        Administrative Rulemaking Act  and              c   is directed by the physician, as that term is defined in Section           or Section                 , who issues the prescription to administer the drug.             Section  .  Effective date.                  Except as provided in Subsection    , this bill takes effect on May  ,     .                  The amendments to Sections      b     and      b     take effect on October  ,            .  